Search research articles
Contact Us
Filters
Showing results (71-80 of 213) with videos related to
Page
of 22
Sort By:
Clinical Genitourinary Cancer
|
October 9, 2022
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer
David J VanderWeele, Masha Kocherginsky, Sabah Munir, et al.
Investigational New Drugs
|
August 6, 2010
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
Bryan J Schneider, Gregory P Kalemkerian, Deborah Bradley, et al.
Cancer
|
June 29, 2006
The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894
Tomasz M Beer, Catherine M Tangen, Lisa B Bland, et al.
Investigational New Drugs
|
April 7, 2010
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease
Robert Dreicer, Jorge Garcia, Maha Hussain, et al.
The Journal of Urology
|
September 18, 2007
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
R Bruce Montgomery, Bryan Goldman, Catherine M Tangen, et al.
European Urology
|
June 21, 2025
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial
Marc-Oliver Grimm, Matthew Smith, Maha Hussain, et al.
Future Oncology (London, England)
|
June 3, 2022
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial
Matthew R Smith, Maha Hussain, Fred Saad, et al.
Cancer
|
August 28, 2009
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
Deborah Bradley, Dana Rathkopf, Rodney Dunn, et al.
Metabolites
|
July 12, 2020
Potential Metabolite Nymphayol Isolated from Water Lily (<i>Nymphaea stellata</i>) Flower Inhibits MCF-7 Human Breast Cancer Cell Growth via Upregulation of Cdkn2a, pRb2, p53 and Downregulation of PCNA mRNA Expressions
Laila Naif Al-Harbi, Pandurangan Subash-Babu, Manal Abdulaziz Binobead, et al.
JAMA Oncology
|
August 28, 2020
Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review
Sean Sachdev, Peter Carroll, Howard Sandler, et al.
Page
of 22
Search research articles
Search
Showing results (71-80 of 213) with videos related to
Sort By:
Page
of 22
Clinical Genitourinary Cancer
|
October 9, 2022
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer
David J VanderWeele, Masha Kocherginsky, Sabah Munir, et al.
Investigational New Drugs
|
August 6, 2010
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
Bryan J Schneider, Gregory P Kalemkerian, Deborah Bradley, et al.
Cancer
|
June 29, 2006
The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894
Tomasz M Beer, Catherine M Tangen, Lisa B Bland, et al.
Investigational New Drugs
|
April 7, 2010
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease
Robert Dreicer, Jorge Garcia, Maha Hussain, et al.
The Journal of Urology
|
September 18, 2007
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
R Bruce Montgomery, Bryan Goldman, Catherine M Tangen, et al.
European Urology
|
June 21, 2025
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial
Marc-Oliver Grimm, Matthew Smith, Maha Hussain, et al.
Future Oncology (London, England)
|
June 3, 2022
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial
Matthew R Smith, Maha Hussain, Fred Saad, et al.
Cancer
|
August 28, 2009
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
Deborah Bradley, Dana Rathkopf, Rodney Dunn, et al.
Metabolites
|
July 12, 2020
Potential Metabolite Nymphayol Isolated from Water Lily (<i>Nymphaea stellata</i>) Flower Inhibits MCF-7 Human Breast Cancer Cell Growth via Upregulation of Cdkn2a, pRb2, p53 and Downregulation of PCNA mRNA Expressions
Laila Naif Al-Harbi, Pandurangan Subash-Babu, Manal Abdulaziz Binobead, et al.
JAMA Oncology
|
August 28, 2020
Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review
Sean Sachdev, Peter Carroll, Howard Sandler, et al.
Page
of 22